Midostaurin (PKC412, Rydapt®) is an oral multiple tyrosine kinase inhibitor. 
Main targets are the kinase domain receptor, vascular endothelial-, platelet 
derived-, and fibroblast growth factor receptor, stem cell factor receptor 
c-KIT, as well as mutated and wild-type FLT3 kinases. Midostaurin was approved 
by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) 
for acute myeloid leukemia with activating FLT3 mutations in combination with 
intensive induction and consolidation therapy as well as aggressive systemic 
mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm 
(SM-AHN) or mast cell leukemia (MCL). Several clinical trials are active or are 
planned to further investigate the role of midostaurin in myeloid malignancies 
and mastocytosis.